Connect with us

Hi, what are you looking for?

Stock

Kennedy would keep legal fees from Merck cases if confirmed

By Dan Levine and Mike Spector

(Reuters) – Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck (NSE:PROR) if he is confirmed as President Donald Trump’s secretary of the U.S. Department of Health and Human Services, according to a federal ethics disclosure made public on Wednesday.

Kennedy, who ended his own presidential campaign last year to endorse Trump, is set for a U.S. Senate hearing on his nomination next week. As HHS secretary, Kennedy would wield enormous influence over the pharma industry, and the nomination is opposed by several health and consumer organizations over Kennedy’s role in sowing doubt about the safety and efficacy of vaccines.

Reuters reported last week that Kennedy played an instrumental role in organizing mass litigation against Merck over its human papillomavirus shot Gardasil. One of the main lawyers suing Merck, Michael Baum, told Reuters that Kennedy “taught us” how to pursue Gardasil claims outside a special government-run vaccine compensation program that limits pharma company liability.

Kennedy has an arrangement to earn 10 percent of fees awarded in contingency cases he refers to Baum’s firm WisnerBaum, according to a letter Kennedy wrote to an HHS ethics official released on Wednesday. If confirmed, Kennedy would retain that financial interest in cases that do not directly impact the U.S. government, the letter said.

Kennedy and Baum did not immediately respond to requests for comment. Merck declined to comment.

High-level U.S. government officials routinely disclose financial interests and potential conflicts during the nomination process.

Kennedy wrote that he is “not an attorney of record” for his WisnerBaum cases. However, Kennedy filed official court appearances in several Gardasil cases, including one set for trial in Los Angeles this week, court dockets show. As of Wednesday, Kennedy had not appeared to have withdrawn from them.

In a separate ethics disclosure, Kennedy reported at least $857,000 from WisnerBaum, and did not specify which cases generated that income. Kennedy has collaborated with WisnerBaum on litigation over Monsanto (NYSE:MON)’s weed killer Roundup.

The Gardasil lawsuits allege Merck had fraudulently advertised the vaccine as safe, overstating its benefits while concealing knowledge of dangerous side effects. Merck says the cases have no merit and that research supports the safety of its HPV vaccines.

This post appeared first on investing.com






    You May Also Like

    Economy

    A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

    Investing

    Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

    Editor's Pick

    Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

    Latest News

    TikTok’s parent company says it has dismissed an intern who it found had ‘maliciously interfered’ with its artificial intelligence technology effort. In a statement...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 balanceandcharge.com